ABSTRACT:
Increased concentrations of bilirubin glucuronides in blood plasma indicate hepatocellular dysfunction. Elucidation of the transport processes of bilirubin conjugates across the basolateral (sinusoidal) and the canalicular plasma membrane domains of hepatocytes has decisively contributed to our current understanding of the molecular basis of conjugated hyperbilirubinemia in human liver diseases. Under normal conditions, unconjugated bilirubin is taken up into hepatocytes by transporters of the organic anion-transporting polypeptide (OATP) family , followed by conjugation with glucuronic acid, and ATP-dependent transport into bile. This efflux across the canalicular membrane is mediated by multidrug resistance protein 2 (MRP2 or ABCC2), which is a 190 kDa glycoprotein transporting with high-affinity and efficiency monoglucuronosyl bilirubin and bisglucuronosyl bilirubin into bile. MRP2 is hereditarily deficient in human Dubin-Johnson syndrome. Under pathophysiological conditions, such as cholestatic liver injury and MRP2 inhibition, the basolateral efflux pump multidrug resistance protein 3 (MRP3 or ABCC3) is responsible for the occurrence of conjugated hyperbilirubinemia. MRP3 is a glycoprotein with a similar molecular mass as MRP2, with 48 % amino acid identity, and with overlapping substrate specificity. Human MRP3 is the only basolateral efflux pump shown to transport bilirubin glucuronides. In human and rat hepatocytes MRP3/Mrp3 is strongly upregulated under conditions of cholestasis and MRP2 deficiency. This is in line with the concept that basolateral efflux pumps of the hepatocyte compensate for impaired canalicular efflux of compounds into bile, and contribute to balance the rate of uptake or synthesis of compounds in hepatocytes with the capacity for efflux into bile.
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Subfamily of ATP-dependent Transport Proteins
The multidrug resistance proteins MRP2 and MRP3 (systematic names ABCC2 and ABCC3) have received particular attention because of their role in the disposition of anionic conjugates and drugs. In polarized cells, as exemplified by hepatocytes and intestinal epithelia, MRP2 is localized exclusively to the apical and MRP3 to the basolateral plasma membrane (Keppler and Kartenbeck, 1996; König et al., 1999) . Note that MRP1 is neither detectable in the basolateral nor in the canalicular membrane of human hepatocytes (Keppler, 2011a) . Members of the MRP subfamily are unidirectional ATP-dependent efflux pumps in the plasma membrane, as shown originally for MRP1 (Jedlitschky et al., 1994; Leier et al., 1994) and subsequently for recombinant MRP2 (Evers et al., 1998; Cui et al., 1999) . Following the cloning of MRP1 in 1992 (Cole et al., 1992) , human MRP2 was the second member of the MRP subfamily to be identified by molecular cloning and cellular localization in 1996 (reviewed by Nies and Keppler, 2007 gov/gene?term=abcc2). The function of human MRP2 and rat Mrp2 may be described in general terms as ATP-dependent export and detoxification of endogenous and xenobiotic substances and their conjugates (Evers et al., 1998; Cui et al., 1999; Nies and Keppler, 2007 (Zeng et al., 2000; Borst et al., 2007; Nies and Keppler, 2007) .
Both efflux pumps share many common substrates, most notably conjugates of lipophilic compounds with glucuronic acid (Borst et al., 2007; Nies and Keppler, 2007; Keppler, 2011a) . Inhibitors, including several drugs, as well as some activators of MRP2 have been extensively characterized by use of inside-out oriented plasma membrane vesicles (Pedersen et al., 2008) . Drugs which are potent in vitro inhibitors of MRP2 include terfenadine, fendiline, tamoxifen, in addition to inhibitory compounds such as the quinoline derivative MK-571, indocyanine green, bromosulfalein, and cyclosporin A (Pedersen et al., 2008) . As exemplified by MK-571, these compounds need not be selective inhibitors for MRP2 (Keppler, 2011a).
MRP3 and MRP2 share an amino acid identity of 48 %. The localization of MRP3 to the basolateral (sinusoidal) membrane of human hepatocytes (König et al., 1999; Kool et al., 1999) and the demonstration that it transports bilirubin glucuronides (Lee et al., 2004) have been decisive for our understanding of conjugated hyperbilirubinemia in cholestasis and under conditions of impaired MRP2 function. In addition, intestinal epithelia are of interest with respect to the basolateral localization of MRP3 in extrahepatic tissues (Scheffer et al., 2002; Rost et al., 2002) , since bilirubin glucuronides formed by UDP-glucuronosyltransferase 1A1 (UGT1A1) in intestinal epithelia (Tukey and Strassburg, 2000) can be effluxed via MRP3 into blood and may thus contribute to the pool of conjugated bilirubin in serum (Fujiwara et al., 2012) . 
Transport of Unconjugated Bilirubin into Human Hepatocytes
Pioneering studies using intravenously injected 14 C-labeled bilirubin in rats and humans demonstrated that the disposition of unconjugated and conjugated bilirubin is almost quantitatively determined by uptake into hepatocytes, followed by elimination into bile (Arias et al., 1961; Schmid and Hammaker, 1963) . Extrahepatic, particularly intestinal, uptake and glucuronidation may play an additional role in preventing hyperbilirubinemia under some conditions, such as the impaired hepatocellular uptake in Rotor syndrome 
(ii) The potent inhibition of OATP1B1 by indinavir, cyclosporin A, and rifamycin SV may lead to drug-induced unconjugated hyperbilirubinemia observed in the clinic (Campbell et al., 2004) .
(iii) A genetic polymorphism in the gene encoding human OATP1B1 causing impaired transport activity was associated with a significant increase of unconjugated bilirubin in serum (Zhang et al., 2007) . what extent additional uptake transporters, such as human OATP2B1, further contribute to this uptake. OATP1A2, which is not expressed in hepatocytes but, among other sites, in the blood-brain barrier (Bronger et al., 2005) , also seems capable of transporting unconjugated bilirubin (van de Steeg et al., 2013) .
Transport of Conjugated Bilirubin by Human Hepatocytes
Four plasma membrane proteins of human hepatocytes were shown to transport monoglucuronosyl bilirubin and bisglucuronosyl bilirubin (the latter chemically correct name is preferred to bilirubin diglucuronide, which is the more conventionally used term): (iii) MRP3 in the sinusoidal membrane is an efficient efflux pump for bilirubin glucuronides (Lee et al., 2004) . Under normal conditions, unconjugated bilirubin is converted in the endoplasmic reticulum to monoglucuronosyl bilirubin and bisglucuronosyl bilirubin by UGT1A1
(reviewed by Tukey and Strassburg, 2000) followed by MRP2-mediated efflux across the canalicular membrane into bile (reviewed by Nies and Keppler, 2007; Keppler, 2012) . However, when the formation and/or the uptake of bilirubin glucuronides exceeds the transport capacity of MRP2 in the canalicular membrane, the sinusoidal efflux via MRP3 provides a pathway for compensation, which leads to urinary excretion. This is exemplified by the MRP2 deficiency of Dubin-Johnson syndrome (Kartenbeck et al., 1996; Keppler and Kartenbeck, 1996) , which is associated with urinary excretion of bilirubin glucuronides, and an upregulation of MRP3 in the sinusoidal membrane (König et al., 1999) . In accordance with the observations in human liver, Mrp2-deficient mutant rats and obstructive cholestasis in rats exhibit a strong (more than 50-fold) upregulation of sinusoidal Mrp3 protein (Ogawa et al., 2000; Donner and Keppler, 2001; Soroka et al., 2001 ).
Efflux from hepatocytes into sinusoidal blood via MRP3 also enables reuptake of bilirubin glucuronides by more downstream (more centrally localized) hepatocytes in the sinusoid by OATP1B1 and OATP1B3 (van de Steeg et al., 2012) . Such a cycle of efflux and reuptake during percolation along the sinusoid was originally proposed for bile acids in hepatocytes and liver lobules, which can be effluxed across the sinusoidal membrane by MRP4 and re-enter hepatocytes via the sodium-dependent taurocholate-transporting polypeptide (NTCP) and OATP1B1 and OATP1B3 (Rius et al., 2006; Keppler, 2011b 
Predominantly Conjugated Hyperbilirubinemia in Rotor Syndrome
The molecular basis of the rare syndrome described by Rotor et al. (Rotor et al., 1948) was elucidated recently and shown to result from the combined hereditary deficiency of 
Predominantly Conjugated Hyperbilirubinemia in Dubin-Johnson Syndrome
The Dubin-Johnson syndrome is a rare autosomal recessively inherited disorder characterized by a predominantly conjugated mild hyperbilirubinemia and deposition of a dark pigment in hepatocytes (reviewed by Chowdhury et al., 2001) . The incidence of Dubin-Johnson syndrome ranges from 1:1,300 among Iranian Jews to 1:300,000 in a Japanese population. The absence of a functionally active MRP2 protein from the human hepatocyte canalicular membrane has been recognized as the molecular basis of this syndrome (Kartenbeck et al., 1996; Keppler and Kartenbeck, 1996) . In line with the established transport function and substrate specificity of MRP2 (reviewed by Nies and Keppler, 2007) , the hepatic elimination of diagnostic organic anions into bile is impaired in Dubin-Johnson syndrome (Chowdhury et al., 2001 ). Many sequence variants in the gene encoding human MRP2 were identified in these patients, including nonsense mutations leading to a premature stop codon (Paulusma et al., 1997) , missense mutations (Toh et al., 1999; Mor-Cohen et al., 2001) , and a deletion mutation leading to the loss of two amino acids from the second nucleotide-binding domain (Tsujii et al., 1999) . conjugated hyperbilirubinemia would be expected as a result of MRP2 deficiency.
However, various studies demonstrated that the relative amount of unconjugated serum bilirubin in this syndrome ranges from 24 % to 38 % of total bilirubin (Kartenbeck et al.,1996; Toh et al., 1999; Tsujii et al., 1999) . Increased unconjugated serum bilirubin levels, in addition to conjugated hyperbilirubinemia, were also observed in Mrp2-deficient mutant rats (Jansen et al., 1985) . So far, neither inhibition of unconjugated bilirubin uptake into hepatocytes nor deconjugation by glucuronidases have been demonstrated as possible explanations.
Dubin-Johnson syndrome (reviewed by Chowdhury et al., 2001 ) as well as Rotor syndrome (Rotor et al., 1948; Jirsa et al., 2012) may be considered as non-diseases.
The predominantly conjugated hyperbilirubinemia is mild because of the compensation by alternative elimination pathways leading to urinary excretion of bilirubin glucuronides.
However, overloading or drug-induced inhibition of the alternative elimination pathways, such as hepatocellular MRP3-mediated efflux, may be a risk factor leading to hepatotoxicity, as discussed by van de Steeg et al., 2012 .
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